0000000000281213

AUTHOR

Milo Frattini

showing 2 related works from this author

Non-small cell lung cancer (NSCLC), EGFR downstream pathway activation and TKI targeted therapies sensitivity: Effect of the plasma membrane-associat…

2017

Adenocarcinoma of Non-Small Cell Lung Cancer (NSCLC) is a severe disease. Patients carrying EGFR mutations may benefit from EGFR targeted therapies (e.g.: gefitinib). Recently, it has been shown that sialidase NEU3 directly interacts and regulates EGFR. In this work, we investigate the effect of sialidase NEU3 overexpression on EGFR pathways activation and EGFR targeted therapies sensitivity, in a series of lung cancer cell lines. NEU3 overexpression, forced after transfection, does not affect NSCLC cell viability. We demonstrate that NEU3 overexpression stimulates the ERK pathway but this activation is completely abolished by gefitinib treatment. The Akt pathway is also hyper-activated upo…

Genetics and Molecular Biology (all)0301 basic medicineOncologyMAPK/ERK pathwayLung NeoplasmsColorectal cancerCell Membraneslcsh:Medicinenon-small cell lung cancer (NSCLC)BiochemistryLung and Intrathoracic TumorsAntineoplastic Agent0302 clinical medicineProtein-Tyrosine KinaseCarcinoma Non-Small-Cell LungMedicine and Health SciencesPost-Translational ModificationPhosphorylationNon-Small-Cell Lunglcsh:ScienceTumorMultidisciplinaryBlottingGefitinibTransfectionProtein-Tyrosine KinasesBIO/10 - BIOCHIMICAErbB ReceptorsOncology030220 oncology & carcinogenesisAdenocarcinomaPhosphorylationHyperexpression TechniquesElectrophoresis Polyacrylamide GelCellular Structures and OrganellesWesternReceptorHumanmedicine.drugSignal TransductionResearch ArticleElectrophoresismedicine.medical_specialtyBlotting WesternNeuraminidaseAntineoplastic AgentsReal-Time Polymerase Chain ReactionTransfectionResearch and Analysis MethodsCell Line03 medical and health sciencesGefitinibInternal medicineCell Line TumormedicineGeneticsGene Expression and Vector TechniquesHumansPoint MutationMolecular Biology TechniquesMolecular BiologyPI3K/AKT/mTOR pathwayColorectal CancerMolecular Biology Assays and Analysis TechniquesPolyacrylamide GelBiochemistry Genetics and Molecular Biology (all)Epidermal Growth Factorbusiness.industryCarcinomalcsh:RCell MembraneQuinazolineCancers and NeoplasmsBiology and Life SciencesProteinsCell Biologymedicine.diseaserespiratory tract diseasesNon-Small Cell Lung CancerLung Neoplasm030104 developmental biologyAgricultural and Biological Sciences (all)MutationQuinazolineslcsh:QReceptor Epidermal Growth FactorAntineoplastic Agents; Blotting Western; Carcinoma Non-Small-Cell Lung; Cell Line Tumor; Cell Membrane; Electrophoresis Polyacrylamide Gel; Humans; Lung Neoplasms; Neuraminidase; Protein-Tyrosine Kinases; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor Epidermal Growth Factor; Signal Transduction; Biochemistry Genetics and Molecular Biology (all); Agricultural and Biological Sciences (all)businessPloS one
researchProduct

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study

2015

OBJECTIVE: We aimed to better clarify the role of germline variants of the FCG2 receptor, FCGR2A-H131R and FCGR3A-V158F, on the therapeutic efficacy of cetuximab in metastatic colorectal cancer (mCRC). A large cohort with sufficient statistical power was assembled.DESIGN: To show a HR advantage of 0.6 in progression-free survival (PFS) for FCGR2A-HH versus the rest and FCGR3A-VV versus the rest, with an 80% power, 80 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) wild-type (KRAS-WT) and 52 KRAS-WT patients are required, respectively. This leads to a total sample size of 952 and 619 patients, respectively. Samples were collected from 1123 mCRC patients from 15 European centres treated wit…

OncologyMaleReceptors IgG/geneticsGenotyping TechniquesColorectal cancermedicine.medical_treatmentCetuximabmedicine.disease_causeGenetic PolymorphismsErbB Receptors/antagonists & inhibitorsNeoplasm MetastasisAntibody Targeted TherapyImmune ResponseAged 80 and overbiologyCetuximabGastroenterologyColorectal Neoplasms/drug therapyMiddle AgedErbB ReceptorsSurvival RateAntibodies Monoclonal Humanized/therapeutic useFemaleKRASAntibodyColorectal Neoplasmsmedicine.drugAdultmedicine.medical_specialtyAntineoplastic AgentsAntibodies Monoclonal HumanizedDisease-Free SurvivalYoung AdultRefractoryInternal medicinemedicineHumansneoplasmsGerm-Line MutationAgedColorectal CancerChemotherapyPolymorphism Geneticbusiness.industryReceptors IgGAntineoplastic Agents/therapeutic usemedicine.diseasedigestive system diseasesOxaliplatinIrinotecanImmunologybiology.proteinbusinessGenotyping Techniques/standards
researchProduct